Rationale Identifying the etiological factors in anxiety and depression is critical to develop more efficacious therapies. The inhibitory serotonin 1A receptors (5-HT 1A R) located on 5-HT neurons (autoreceptors) limit antidepressant responses and their expression may be increased in treatment-resistant depressed patients. Objectives Recently, we reported that intranasal administration of modified small interference RNA (siRNA) molecules targeting 5-HT 1A R in serotonergic neurons evoked antidepressant-like effects. Here we extended this finding using marketed siRNAs against 5-HT 1A R (1A-siRNA) to reduce directly the 5-HT 1A autoreceptor expression and evaluate its biological consequences under basal conditions and in response to stressful situations. Methods Adult mice were locally infused with vehicle, nonsense siRNA, and 1A-siRNA into dorsal raphe nucleus (DR). 5-HT 1A R knockout mice (1A-KO) were also used. Histological approaches, in vivo microdialysis, and stressrelated behaviors were performed to assess the effects of 5-HT 1A autoreceptor knockdown. Results Intra-DR 1A-siRNA infusion selectively reduced 5-HT 1A R mRNA and binding levels and canceled 8-OH-DPAT-induced hypothermia. Basal extracellular 5-HT in medial prefrontal cortex (mPFC) did not differ among treatments. However, 1A-siRNA-treated mice displayed less immobility in the tail suspension and forced swim tests, as did 1A-KO mice. This was accompanied by a greater increase in prefrontal 5-HT release during tail suspension test. Moreover, intra-DR 1A-siRNA infusion augmented the increase of extracellular 5-HT in mPFC evoked by fluoxetine, up to the level in 1A-KO mice. Conclusion Together with our previous report, the present results indicate that acute suppression of 5-HT 1A autoreceptor
Introduction
Major depression is a severe and heterogeneous psychiatric syndrome with high prevalence and socioeconomic impact (Andlin-Sobocki et al. 2005; Murray and López 1997) . The serotonergic system has been implicated in the etiology and treatment of depression and other mood disorders (Krishnan and Nestler 2008) . Serotonin 1A receptor (5-HT 1A R) plays a key inhibitory role in brain function due to its coupling to inwardrectifying K + channels (Andrade et al. 1986; Innis and Aghajanian 1987) . It is located presynaptically (as autoreceptor) on serotonergic neurons in the raphe nuclei and postsynaptically on glutamatergic and GABAergic neurons in corticolimbic areas (Pompeiano et al. 1992; Riad et al. 2000; Santana et al. 2004) . Negative feedback inhibition of serotonergic activity is mediated by activation of 5-HT 1A autoreceptors (Innis and Aghajanian 1987; Piñeyro and Blier 1999) , which reduces the discharge rate of serotonergic neurons and terminal serotonin (5-HT) release (Artigas et al. 1996; Blier and deMontigny 1994) .
Antidepressant drugs, including the selective 5-HT reuptake inhibitors (SSRIs), markedly increase extracellular 5-HT in the raphe nuclei, thus acutely activating this negative feedback (Adell and Artigas 1991; Romero and Artigas 1997) . Upon chronic treatment, 5-HT 1A autoreceptors desensitize, leading to the recovery of serotonergic activity and increased 5-HT release (Artigas et al. 1996; Blier and deMontigny 1994) . Likewise, 5-HT 1A R knockout mice display enhanced neurochemical responses to SSRIs Knobelman et al. 2001) . Prevention of this negative feedback with the non-selective 5-HT 1A R antagonist pindolol augments antidepressant effects (Artigas et al. 1994; Portella et al. 2011) . However, the clinical applicability of selective 5-HT 1A R antagonists is limited by their comparable action at pre-and postsynaptic 5-HT 1A R and the need to preserve postsynaptic 5-HT 1A R activation for clinical effects (Haddjeri et al. 1998) .
Furthermore, differences in 5-HT 1A R expression are associated with affective disorders and antidepressant response. Hence, individuals with high 5-HT 1A autoreceptor expression, including those with a functional polymorphism in the promoter region of Htr1a gene, are more susceptible to depression and suicide and respond poorly to antidepressant therapy (Fakra et al. 2009; Lemonde et al. 2003; Neff et al. 2009; Stockmeier et al. 1998; Sullivan et al. 2009 ).
The study of the relative role of the different 5-HT 1A R populations in the pathophysiology and treatment of psychiatric disorders has been limited by the lack of pharmacological and genetic tools selective for pre-and postsynaptic 5-HT 1A R (Gleason et al. 2010) . Richardson-Jones et al. (2010) reported antidepressant-like responses in transgenic mice with a moderate reduction of 5-HT 1A autoreceptors.
Small interference RNA (siRNA) is effective, safe, and well tolerated in mice and non-human primates (Heidel et al. 2004; Kumar et al. 2007; Li et al. 2005; Thakker et al. 2004 Thakker et al. , 2005 . We recently reported that sertraline-conjugated siRNA molecules (Patent PCT/EP2011/056270) designed to silence the 5-HT 1A R mRNA only in 5-HT neurons evoke antidepressant-like effects in mice (Bortolozzi et al. 2012 ). Here, we extend these findings using unmodified siRNA molecules against 5-HT 1A R under the working hypothesis that selective siRNA-induced 5-HT 1A autoreceptor reduction would increase resilience to stressful situations through an increase of the serotonergic tone.
Material and methods

Animals
Male homozygous 5-HT 1A R knockout (1A-KO) (Parks et al. 1998 ) and wild-type mice on the same background (C57BL/6J) were used. Mice (9-12 weeks old) were housed under controlled conditions (22±1°C; 12 h light/dark cycle). Food and water were provided ad libitum. All animal procedures were conducted in accordance with the standard ethical guidelines (European Union regulations L35/118/12/ 1986) and approved by the local ethical committee of the School of Medicine, University of Barcelona. siRNAs and treatments Four siRNAs targeting the 5-HT 1A R (1A-siRNA1 to 1A-siRNA4) (nt 633-651, 852-870, 1,889-1,907 , and 2,167-2,185, GenBank accession #NM_008308) were chosen and infused as a mixture, containing an equal amount of each siRNA duplex. Additionally, an unrelated siRNA duplex with no homology to mouse genome was used as negative control (nonsense siRNA-ns-siRNA). The siRNA sequences are shown in Table 1 . All siRNAs were dissolved following the manufacturer's protocol (Ambion, Madrid, Spain) and stored at −30°C until use.
Mice were anesthetized (pentobarbital, 40 mg/kg, i.p.) and silica capillary microcannulae (110 μm OD and 40 μm ID; Polymicro Technologies, Madrid, Spain) were stereotaxically implanted into the dorsal raphe nucleus (DR; coordinates in mm: AP -4.5; ML -1.0; DV -4.4; with a lateral angle of 20°) (Franklin and Paxinos 2008) . Some animals were also implanted with a microdialysis probe in medial prefrontal cortex (mPFC) (see below). Microinfusion experiments were conducted 24 h after surgery in awake mice using a precision pump at a rate of 0.5 μl/min (WPI model sp220i, Aston, Stevenage, UK). A mixture of the four 1A-siRNAs were prepared in artificial cerebrospinal fluid (aCSF) (125 mM NaCl, 2.5 mM KCl, 1.26 mM CaCl 2 , and 1.18 mM MgCl 2 with 5 % glucose) and administered at the doses of 2.5 or 10 μg of 1A-siRNA per mouse into DR (1 ul aliquots). Nonsense siRNA was infused at the same doses. Intra-DR siRNA infusion was repeated 24 h later (two administrations in total). Controls and 1A-KO mice were subjected to the same experimental procedure and received aCSF.
RNA isolation and quantitative RT-PCR analysis
Mice were killed 24 h after treatments. The brain was removed and placed on an ice-cold plate. Midbrain sections (1 mm thick) containing the raphe nuclei were dissected out using a Mouse Brain Matrix (Ted Pella, Madrid, Spain), quickly frozen on dry ice, and stored at −80°C. Total RNA was isolated with Trizol solution and rehydrated in 10 μl RNAse-free water to a final RNA concentration of 0.5 μg/μl. Quantitative RT-PCR was made as previously described (Bortolozzi et al. 2012) . The primers used are summarized in Table 1 .
In situ hybridization and receptor autoradiography Mice were killed by pentobarbital overdose, and the brains rapidly removed, frozen on dry ice, and stored at −20°C. Tissue sections, 14 μm thick, were cut using a microtome cryostat (HM500 OM, Microm, Walldorf, Germany), thawmounted onto 3-aminopropyltriethoxysilane-coated slides (Sigma-Aldrich, Madrid, Spain), and kept at −20°C until use.
For 5-HT 1A R mRNA, three oligonucleotides were used simultaneously, complementary to bases 1-48, 763-810, and 1,219-1,266 (GenBank accession #NM_012585). Probes labeling and in situ hybridization procedures were carried out as described previously (Bortolozzi et al. 2012; Santana et al. 2004 ).
The autoradiographic binding assays for 5-HT 1A and 5-HT 1B receptors and serotonin transporter (SERT) Bortolozzi et al. 2012; D'Amato et al. 1987; Pazos and Palacios 1985) were performed using the following radioligands: Table 2 . The films were analyzed by microdensitometry using a previously described method (Bortolozzi et al. 2012) . (Adell et al. 2002) . The probes were continuously perfused (WPI model sp220i) with aCSF, and the dialysate was collected every 20 min for DA and every 6 or 30 min for 5-HT. Monoamine concentrations were analyzed by HPLC-amperometric detection (Hewlett Packard-1049, Palo Alto, CA, USA) at +0.75 and +0.60 V for DA and 5-HT, respectively, with detection limits of 2 fmol/sample. Baseline monoamine levels were calculated as the average of four pre-drug samples or ten pre-TST samples, respectively. Following sample collection, brains were removed and sectioned to ensure proper probe placement after cresyl-violet staining.
Behavioral and physiological testing
Mice were tested at 24 h after treatments. All tests were performed between 10:00 a.m. and 14:00 p.m. On test days, animals were transported to the dimly illuminated behavioral laboratory and were left undisturbed for at least 1 h before testing. Animals did not undergo more than one behavioral assay.
Elevated plus-maze test (EPM)
EPM was performed using a cross maze with 16×5 cm arms illuminated from the top (100 lx 
Tail suspension test
Mice were suspended 30 cm above the bench by adhesive tape placed approximately 1 cm from the tip of the tail. Mice were monitored and recorded using a video camera system (Smart, Panlab), and the time spent immobile was recorded for 6 min. In an additional group, the mPFC 5-HT concentration was simultaneously measured during TST paradigm by in vivo microdialysis (see above).
Forced swim test (FST)
Mice were individually placed into a clear cylinder (15 cm diameter, 30 cm height) containing 20 cm of water maintained at 24-25°C, essentially as described by Porsolt et al. (1978) . In this test, immobility of the mouse was scored in 2 min bins for a total of 6 min using a video camera system (Smart, Panlab).
8-OH-DPAT-induced hypothermia
Body temperature was measured intrarectally using a lubricated probe inserted~2 cm and a digital thermometer (AZ9882, Panlab) as previously described (Bortolozzi et al. 2012 ). Mice received 8-OH-DPAT 1 mg/kg i.p. and body RT room temperature, i.c.b. ice-cold buffer temperature was recorded every 15 min for a total of 120 min.
Statistical analysis
Data are expressed as means ± SEM. One-or two-way ANOVA was used to compare data from mRNA expression, autoradiography, and neurochemical and behavioral analyses in the experimental groups, as appropriate, followed by post hoc test (Newman-Keuls). Student's t test was used to identify significant difference in the FST. The level of significance was set at p<0.05 (two-tailed).
Results
Selective silencing of presynaptic 5-HT 1A R expression by local 1A-siRNA infusion into mice DR
We first examined the feasibility of reducing directly 5-HT 1A autoreceptor expression in the DR of adult mice by local infusion of 1A-siRNA molecules. The 1A-siRNA mixture was applied in a volume of 1 μl at two concentrations (2.5 or 10 mg/ml solution) on two consecutive days, giving a total amount of 1A-siRNA of 5 and 20 μg (0.3 and 1.4 nmol, respectively).
In situ hybridization experiments revealed that the local infusion of 5 and 20 μg 1A-siRNA evoked a dose-dependent decrease of 5-HT 1A R mRNA levels in the DR at 1 day postadministration (to 82±6 and 44±5 % of the vehicle-treated group). Mice treated with 20 μg 1A-siRNA had a significant reduction of 5-HT 1A R mRNA compared to vehicle or nssiRNA-treated mice (Fig. 1a, b) . Two-way ANOVA showed significant effects of group [F(2, 13) H]-8-OH-DPAT binding also revealed a reduction of DR 5-HT 1A R density in mice treated with 5 or 20 μg 1A-siRNA (to 70±5 and 50±5 % of vehicle-treated mice) compared with that in control groups (vehicle and ns-siRNA) (Fig. 1a, b) . Two-way ANOVA showed a significant effect of group [F(2, 45)016.95, p< 0.001], but no effect of dose nor interaction group-by-dose. The suppression of presynaptic 5-HT 1A R in the DR was observed at the three anteroposterior coordinates examined.
Intra-DR 1A-siRNA administration did not alter 5-HT 1A R expression in the median raphe nucleus (MnR), indicating a restricted siRNA diffusion after local application with capillary microcannula (Fig. 1c, Supplementary Fig. S1 ). Likewise, 5-HT 1A R density in forebrain areas rich in 5-HT 1A R, such as the prefrontal cortex, hippocampal formation, and entorhinal cortex, remained also unaffected (Fig. 1d, e) .
Furthermore, we examined the expression of potentially unintended targets by measuring mRNA and binding densities of two related genes that are localized in serotonergic neurons: SERT and 5-HT 1B R. Neither SERT and 5-HT 1B R mRNAs nor their respective binding sites were affected by intra-DR 1A-siRNA infusion (Fig. 2a-e) . Moreover, 1A-siRNA application did not change the mRNA expression of pro-inflammatory cytokines such as TNF-α (relative gene expression: control, 1.0±0.2; ns-siRNA 0.7± 0.2; 1A-siRNA, 0.8±0.2; n05-6) and INF-γ (relative gene expression: control, 1.0 ± 0.1; ns-siRNA 0.9 ± 0.2; 1A-siRNA, 0.7±0.2; n05-6) in the raphe nuclei.
We next evaluated the time course of 1A-siRNA effects in vivo. We infused the highest dose (20 μg/mice) of 1A-siRNA into the DR, and groups of mice were killed at different times after the last siRNA injection. Autoradiographic binding experiments revealed that the DR 5-HT 1A R density was significantly lower in 1A-siRNAtreated mice than in the respective control groups 1 and 3 days post-administration, with a recovery of 5-HT 1A R density to control values at 6 and 12 days postadministration (Fig. 3a, b) . One-way ANOVA showed a significant effect of group at day 1 [F(2, 10)015.62, p< 0.001] and day 3 [F(2, 13)010.32, p<0.01] after infusion.
Altered agonist response in 5-HT 1A autoreceptor knockdown mice
To directly confirm the in vivo functional impact of DR 5-HT 1A R suppression indicated by autoradiography (Fig. 3a,  b) , we assessed the hypothermic response mediated by the activation of presynaptic 5-HT 1A R in mice (Martin et al. 1992) . We administered the 5-HT 1A R agonist, 8-OH-DPAT (1 mg/kg, i.p.), to control (vehicle and ns-siRNA), 1A-siRNA-treated mice, and constitutive 1A-KO mice. Vehicle and ns-siRNA-treated mice displayed the expected hypothermic response to 8-OH-DPAT, which was absent in 1A-siRNA-treated mice at days 1-3 and was recovered at days 6-12 post-administration, in agreement with the change in 5-HT 1A autoreceptors levels. 1A-KO mice showed no hypothermic response at any time (Fig. 3c ). Significant differences were observed at day 1: effect of group [F(3, 24) We next examined how decreased 5-HT 1A autoreceptor expression induced by intra-DR 1A-siRNA infusion translated into a distal regulation of 5-HT and DA release in the forebrain. We performed pharmacological studies in the mPFC of freely moving mice using microdialysis. No difference was observed in baseline 5-HT and DA concentration between the various groups of mice (Table 3) . The 5-HT 1A R agonist 8-OH-DPAT (0.5 mg/kg, i.p.) reduced extracellular 5-HT concentration to~40 % of baseline in mPFC of control groups, but not in 1A-siRNA-treated or 1A-KO mice [effect of group, F(3, 21)011.29, p<0.01; time, F(14, 294)04.40, p<0.001; and time-by-group interaction, F(42, 294)03.57, p<0.001] (Fig. 4a) .
Postsynaptic 5-HT 1A R in mPFC is involved in the control of mesocortical dopamine (DA) activity and local DA release (Díaz-Mataix et al. 2005) . To confirm the absence of functional changes on mPFC 5-HT 1A R by intra-DR 1A-siRNA infusion, we assessed the effect of the selective 5-HT 1A R agonist, BAYx3702 on extracellular DA in mPFC of these mice. Local BAYx3702 infusion at 3 μM by reverse dialysis increased DA concentration in mPFC of vehicle, ns-siRNA, and 1A-siRNA-treated mice to a similar extent, with no effect on 1A-KO mice [effect of group, F(3, 12)010.02, p< 0.01; time, F(14, 168)017.80, p<0.001; and time-bygroup interaction, F(42, 168)02.74, p<0.001, without (Fig. 4b) . These results are consistent with the above 5-HT 1A R binding data and indicate that intra-DR 1A-siRNA infusion did not alter cortical 5-HT 1A R expression and function.
Unchanged anxiety-like behavior and altered response to depression/stress-related paradigms in 5-HT 1A autoreceptor knockdown mice
To evaluate the role of presynaptic 5-HT 1A R in anxietylike behavior in adulthood, we used the EPM paradigm. Vehicle and 1A-siRNA-treated mice showed similar behavioral responses during exposure to the EPM, whereas 1A-KO mice exhibited an anxiety-like behavior (Fig. 5a ). One-way ANOVA indicated a significant effect of group for entries [F(2, 35) Additional to its role in anxiety, several studies suggest that 5-HT 1A R levels influence behavioral resilience to stressful situations, i.e., individuals with higher 5-HT 1A R expression are more susceptible to depression and suicide (Lemonde et al. 2003; Neff et al. 2009 ). We therefore examined the potential antidepressant-like responses evoked by intra-DR 1A-siRNA application in adult mice using two depression-related stress paradigms: TST and FST. In both tests, immobility is scored as a measure of behavioral despair (Lucki 1997) . In TST, 1A-siRNA-treated and 1A-KO mice showed a greater propensity to escape and a shorter immobility time than vehicle controls [effect of group, F(2, 36)0 25.25, p<0.001] (Fig. 5b) . The intrinsic decreased immobility shown by 5-HT 1A autoreceptor knockdown mice in the TST was comparable to that exhibited by control mice after antidepressant treatments (Bortolozzi et al. 2012; Cryan et al. 2005) .
Likewise, mice treated with intra-DR infusion of 1A-siRNA were more active and displayed a reduced (Fig. 5c) . A comparable antidepressant response was observed after acute SSRI fluoxetine administration (Bortolozzi et al. 2012; Cryan et al. 2005) . Two-way ANOVA showed a significant effect of group [F(1, 18)016.88, p<0.001] and time [F(2, 36)081.73, p<0.001]. Thus, while low 5-HT 1A autoreceptor expression in adulthood does not alter anxiety-like behavior, it elicits a more active response in depression-related tasks such as the TST and the FST.
Increased serotonin levels in 5-HT 1A autoreceptor knockdown mice under a depression/stress-related paradigm and in response to fluoxetine Given the increased resilience to stressful factors in 1A-siRNA-treated mice and the inhibitory control of 5-HT 1A autoreceptors on serotonergic function, we next examined whether this effect was associated to an increased forebrain 5-HT release. We performed in vivo microdialysis in mPFC 3 H]-8-OH-DPAT binding to 5-HT 1A R in DR of 1A-siRNA-treated mice compared with their respective controls at days 1 and 3 post-administration. Conversely, no difference was detected at days 6 and 12 post-administration (n04-7 mice/group, relative optical density was evaluated in two adjacent DR sections at three anteroposterior levels of each mouse and averaged to obtain individual values). **p<0.01, ***p<0.001 versus vehicle and ns-siRNA-treated mice. c Time course of the hypothermic response to the 5-HT 1A R agonist 8-OH-DPAT (1 mg/kg, i.p.). Hypothermia was abolished in 5-HT 1A autoreceptor knockdown mice at days 1 and 3. Constitutive 1A-KO mice, also lacking 8-OH-DPAT-induced hypothermia, were used as positive controls (n06-10 mice/group). *p<0.05, ***p<0.001 versus vehicle and ns-siRNA-treated mice. Values are mean ± SEM simultaneously during the performance of the TST. Despite no significant difference was detected in prefrontal 5-HT concentration at baseline between groups (Table 3) , the dialysate 5-HT increased twofold in 5-HT 1A autoreceptor knockdown mice under TST-induced behavioral despair (Fig. 6a) . Two-way ANOVA showed significant effect of time [F(18, 270) (Fig. 6b) .
Finally, we examined whether the 1A-siRNA-induced changes in 5-HT 1A autoreceptor expression translated into an enhancement of the neurochemical response to an SSRI, as previously observed with the pharmacological blockade of 5-HT 1A R (Artigas et al. 1996; Romero and Artigas 1997) . Mice received a single fluoxetine injection (20 mg/kg, i.p.), which increased extracellular 5-HT concentration in mPFC of all groups, but significantly more in 1A-siRNA-treated and 1A-KO mice [effect of group, F(3, 17)06.45, p<0.01; time, F(14, 238)017.62, p<0.001; and time-by-group interaction, F(42, 238)03.44, p<0.001] (Fig. 7) .
Discussion
In agreement with our recent observations (Bortolozzi et al. 2012 ), the present study shows that direct suppression of presynaptic 5-HT 1A R expression in the DR in adulthood is sufficient to impact on reactivity to stress/depression-related behavior without affecting anxiety-like response. Both sets of independent results are entirely comparable and show that 1A-siRNA is a powerful tool for the efficient and selective silencing of the 5-HT 1A autoreceptor expression in vivo in rodent brain. This procedure provides a number of advances over more classical transgenic mice approaches. First, it allows for spatial and temporal specificity, neither of which is possible using constitutive KO mice. Indeed, we evaluated the effect of 5-HT 1A autoreceptor changes on anxietyand depression-like behaviors in adulthood leaving aside neurodevelopment problems due to the lack of 5-HT 1A R (Gleason et al. 2010; Gross et al. 2002; Heisler et al. 1998; Parks et al. 1998; Ramboz et al. 1998) . Second, the siRNA strategy allows for the examination of the physiological role of receptors/transporters and the subsequent adaptive (5) 6.3±0.6 (6) ns-siRNA 6.1±0.7 (7) 5.5±0.9 (5) 15.6±3.7 (7) 7.6±1.3 (5) 1A-siRNA 5.2±0.9 (6) 5.4±1.1 (5) 15.2±3.7 (7) 9.2±1.4 (7) 1A-KO 6.9±1.0 (4) 6.0±1.3 (5) 18.1±1.2 (6) n.e.
Data are mean ± SEM of the number of animals shown in parentheses. For DA assessing, the aCSF was pumped at 1.5 μl/min and dialysate was collected every 20 min. For 5-HT assessing, the microdialysis probes were perfused with appropriate aCSF at 1.5 or 5.0 μl/min and dialysates were collected every 30 or 6 min, respectively aCSF artificial cerebrospinal fluid, aCSF + citalopram artificial cerebrospinal fluid containing 1 μM citalopram, n.e. not examined Fig. 4 Neurochemical consequences of 1A-siRNA-induced 5-HT 1A autoreceptor knockdown. a Acute 8-OH-DPAT administration (0.5 mg/ kg, i.p.) did not reduce extracellular serotonin concentration in medial prefrontal cortex (mPFC) of 1A-siRNA-treated mice and 1A-KO mice (n05-7 mice/group). **p<0.01 versus vehicle and ns-siRNA-treated mice. b Local activation of postsynaptic 5-HT 1A R in mPFC by the infusion of 3 μM BAYx3702 by reverse dialysis increased extracellular dopamine concentration in vehicle, ns-siRNA, and 1A-siRNA-treated mice, but not in 1A-KO mice (n04 mice/group). **p<0.01 versus vehicle, ns-siRNA, and 1A-siRNA groups. Values are mean ± SEM temporal changes induced on other genes in response to the reduced expression of the target gene (Bortolozzi et al. 2011) .
Pharmacological or molecular approaches-and siRNAs are no exception (Moss and Taylor 2003; Sledz et al. 2003 )-have unintended off-target effects. Some genes containing sequences with incomplete complementarity may be unintentionally silenced by mRNA cleavage (Dykxhoorn Fig. 5 Behavioral consequences of 1A-siRNA-induced 5-HT 1A autoreceptor knockdown. Mice were infused with 20 μg (2×10 μg) 1A-siRNA into dorsal raphe nucleus (DR) and behavioral tests were conducted 24 h after administration. Control and 1A-KO mice received vehicle into DR and were subjected to the same experimental procedure. a Anxiety-like behavior. Unlike 1A-KO mice, vehicle and 1A-siRNA-treated mice showed a similar anxiety-like behavior in the elevated plus maze (EPM), with no differences in the percentage of entries and time spent in open arms (n012-13 mice/group). *p<0.05, **p<0.01, ***p<0.001 versus vehicle and 1A-siRNA-treated mice. b, c Antidepressant-like behaviors. b 1A-siRNA-treated mice displayed a reduced immobility in the tail suspension test (TST), as did constitutive 1A-KO mice (n012-13 mice/group). **p<0.01, ***p<0.001 versus vehicle-treated mice. c 1A-siRNA-treated mice also showed a decreased immobility in the forced swim test (FST) (n010 mice/group). **p<0.01, ***p<0.001 versus vehicle-treated mice. Values are mean ± SEM and Lieberman 2006). Although the rules for predicting in vivo off-target gene regulation are still poorly known, the present results support a specific effect of 1A-siRNA on 5-HT 1A autoreceptor expression restricted to the application site (DR) (Supplementary Fig. S1 ). Hence, presynaptic 5-HT 1A R in the MnR and forebrain postsynaptic 5-HT 1A R were unaffected by intra-DR 1A-siRNA application. Moreover, the same amount of nonsense siRNA infused into the DR did not evoke any change in the 5-HT 1A autoreceptor density. Additionally, other genes expressed by serotonergic neurons, such as SERT or 5-HT 1B R, were unmodified by this approach. It is possible that siRNAs could alter the cellular homeostasis by triggering immune and inflammatory pathways (Judge et al. 2005; Moss and Taylor 2003; Sledz et al. 2003) . However, the 1A-siRNA sequences used herein did not induce pro-inflammatory genes (TNFα, INFγ) as previously described by β-galactosidase-siRNA (Bortolozzi et al. 2012) . The absence of non-specific effects is likely due to the use of low siRNA concentrations, compared with other in vivo brain studies (Thakker et al. 2004 (Thakker et al. , 2005 .
A lower density of 5-HT 1A autoreceptor was observed at 1 and 3 days post-administration of 1A-siRNA and it was recovered at 6 days. This is consistent with the turnover of 5-HT 1A R obtained after its chemical inactivation by Nethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) (Gozlan et al. 1994) . Interestingly, there was a close temporal parallelism between the changes in receptor expression and the functional status of 5-HT 1A autoreceptor in response to the 5-HT 1A R agonist 8-OH-DPAT. However, the magnitude of the effects was markedly different. Thus, a decrease of 5-HT 1A autoreceptor density (44 %) was sufficient to prevent 8-OH-DPAT-mediated responses (fall in extracellular 5-HT and hypothermia), making 1A-siRNA-treated mice to partially behave as constitutive 1A-KO mice. However, the last showed a hyperthermia response following 8-OH-DPAT injection, likely due to the anxious-like response in 1A-KO mice (Heisler et al. 1998; Parks et al. 1998; Pattij et al. 2002; Ramboz et al. 1998) . The "reserve" pool presence of presynaptic 5-HT 1A R was suggested after irreversible EEDQ effect on GPCRs (Bohmaker et al. 1992; Cox et al. 1993 ). Our results, using an entirely different strategy, support the existence of different functional 5-HT 1A autoreceptor pools and suggest that newly synthesized 5-HT 1A autoreceptors are functionally active receptors that mediate the 8-OH-DPAT agonist response.
In coincidence with previous findings Bortolozzi et al. 2004 Bortolozzi et al. , 2012 He et al. 2001; Knobelman et al. 2001; Ramboz et al. 1998; RichardsonJones et al. 2010) , the basal extracellular 5-HT concentration was similar in controls and 1A-siRNA-treated and 1A-KO mice. This also agrees with the absence of major alterations in the firing rate of DR serotonergic neurons in 1A-KO mice Richer et al. 2002) and provides further support to the view that 5-HT 1A autoreceptors are not tonically activated under physiological conditions (Johnson et al. 2002; Mannoury la Cour et al. 2001) . Actually, 5-HT 1A autoreceptors play the role of "safety valves" to maintain the slow and regular discharge of serotonergic Fig. 8 Schematic representation of the balance between presynaptic 5-HT 1A R activation in the raphe nuclei and 5-HT release by nerve terminals in cortical and limbic areas. a In basal conditions, the balance between excitatory and inhibitory inputs onto DR serotonergic neurons (Celada et al. 2001 ) keeps the extracellular 5-HT concentration in the vicinity of serotonergic cell bodies and dendrites below the concentration required to activate 5-HT 1A autoreceptors. b In conditions of increased excitatory inputs, such as during stress, 5-HT release increases in the DR (either somatodendritic or from the dense network of 5-HT axons within the raphe nuclei; Adell et al. 1997 Adell et al. , 2002 . The subsequent 5-HT 1A autoreceptor activation and neuronal hyperpolarization keeps serotonergic cell firing low (typically~1 Hz) and regular, with no effect on firing-dependent terminal 5-HT release. c In a situation of low density or sensitivity of 5-HT 1A autoreceptors (illustrated by a small size of the 5-HT 1A autoreceptors symbol), the above negative feedback does not occur and increased excitatory inputs onto serotonergic neurons translate into a greater terminal 5-HT release in corticolimbic areas that helps to increase resilience to stress (e.g., lower immobility in TST and FST). Similarly, the excess of extracellular 5-HT evoked by SERT blockade with fluoxetine cannot activate the 5-HT 1A autoreceptor-mediated negative feedback (Artigas et al. 1996) , resulting in a greater extracellular 5-HT concentration in forebrain, as shown in the preceding figure neurons in conditions of high excitatory input (Celada et al. 2001 ) such as during stressful conditions (Adell et al. 1997) . In non-stressful conditions, 5-HT release remains at concentrations below those required to activate 5-HT 1A autoreceptors. This may explain the apparent contradiction between decreased presynaptic 5-HT 1A R expression and unchanged 5-HT levels in mPFC. Only when 5-HT 1A autoreceptors are markedly activated by the excess 5-HT induced by SSRIs, the difference in terminal 5-HT levels is evident. Thus, the increase of mPFC 5-HT evoked by fluoxetine was augmented in mice treated with 1A-siRNA to reach the values seen in 1A-KO mice, as previously observed using SSRI + 5-HT 1A R antagonists (Artigas et al. 1996; Romero and Artigas 1997; Scorza et al. 2012) .
Moreover, 1A-siRNA-treated mice showed a marked reduction in immobility versus control mice in standard depression-related stress tests, indicating that the suppression of 5-HT 1A autoreceptors evoked antidepressant-like effects, which were similar to those exhibited by constitutive 1A-KO mice when examined (TST). Hence, the increased 5-HT release in mPFC (and likely other forebrain areas) obtained by down-regulated 5-HT 1A autoreceptor expression would enhance resilience to stressful conditions, as seen here with 1A-siRNA-treated mice in the TST (see scheme in Fig. 8 ). This view is also consistent with the increased raphe firing rate in a model of 5-HT 1A autoreceptor transgenic mice under chronic stress (Richardson-Jones et al. 2010) .
The~44 % knockdown of 5-HT 1A autoreceptor found herein after acute 1A-siRNA infusion was comparable to that reported after prolonged administration of high siRNA concentrations in the brain (Thakker et al. 2004 (Thakker et al. , 2005 . Likewise, the functional consequences of 1A-siRNA-induced 5-HT 1A autoreceptor knockdown are comparable with previous pharmacological and clinical observations using 5-HT 1A R antagonists which attributed a key role to presynaptic 5-HT 1A R in antidepressant therapy (Artigas et al. 1994; Ballesteros and Callado 2004; Portella et al. 2011; Scorza et al. 2012 ). However, unlike pindolol, selective 5-HT 1A R antagonists do not discriminate between pre-and postsynaptic 5-HT 1A R, a lack of regional selectivity that can limit their therapeutic use in SSRI combination studies due to the need to enhance presynaptic serotonergic function without blocking postsynaptic 5-HT 1A R (Ballesteros and Callado 2004; Haddjeri et al. 1998; Scorza et al. 2012) . In view of these limitations, a siRNA-based approach may uncover valid therapeutic strategies, provided that appropriate cellular targeting can be achieved. Indeed, there is a considerable effort in developing improved siRNA delivery and gene silencing in vivo (Baker 2010; Kumar et al. 2007; Song et al. 2005; Soutschek et al. 2004 ). Thus, our efforts are directed to achieving a selective targeting of genes expressed in serotonergic neurons (Bortolozzi et al. 2012 ).
Neuroimaging studies have associated high 5-HT 1A autoreceptor density in humans with a poor reactivity of the amygdala, a brain region important for responses to stress and threatening stimuli (Fakra et al. 2009 ). Further, genetic studies link 5-HT 1A R mutations leading to high levels of 5-HT 1A autoreceptor with higher incidence to mood disorders and poorer response to antidepressants (Lemonde et al. 2003; Neff et al. 2009; Stockmeier et al. 1998) . Our results agree with the hypothesis that 5-HT 1A autoreceptors have a critical role in the treatment of major depression (Bortolozzi et al. 2012; Richardson-Jones et al. 2010) , and they provide support for optimizing therapeutic interventions on the basis of the heterogeneity of patients with regard to function of the 5-HT system.
In summary, together with our recently reported work (Bortolozzi et al. 2012) , the present study indicates that selective 5-HT 1A autoreceptor suppression prevents the self-inhibitory effects of DR 5-HT 1A R activation. The prevention of this physiological negative feedback evokes antidepressant-like responses, likely mediated by an increased capacity of serotonergic neurons to release 5-HT in stressful conditions and also augments the neurochemical effects of fluoxetine. Overall, these observations hold promise for the development of a new class of therapeutics that harnesses the RNAi mechanism to regulate gene expression in serotonergic neuron and help to unveil the complex relationship between stress and the 5-HT system.
